- In Vivo Originals
- Featured Topics
Leadership
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

-
Interviews
The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge
By Ashley YeoWith a product mix that includes high energy consumption imaging, capital equipment and personal health care, Philips has a unique spectrum of challenges in driving low carbon health care. Nevertheless, it has set the bar high in environmental sustainability goals, and is pressing suppliers to follow its lead.

-
Interviews
Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
By David WildBavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.

-
Interviews
Backed By Big Names, Etherna Hopes To Disrupt mRNA Space
By Anju GhangurdeBelgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.

-
Analysis
Philips Healthcare: Targeting Healthtech Market Recovery Via Value Creation
By Ashley YeoQuality issues relating to a historical acquisition have held back Philips Healthcare’s financial performance in the post-COVID phase, while market competitors have been able to chart a less bumpy path through the tail end of the pandemic. All are facing supply chain and inflationary pressures.

-
Analysis
A Candidate’s Market: How Can Medtechs Attract And Retain Staff They Need In 2023?
By Barnaby PickeringAttracting and retaining talent is harder than ever for medtech companies. Changing lifestyles, the expectation that loyalty will be less rewarding than job hopping, and various other economic and social factors have all helped contribute to chronic staffing shortages throughout medtech.

-
Interviews
Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles
By David WildIn December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.

-
Data
Execs On The Move: January 2023
By Barnaby PickeringAn interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

-
Interviews
The Mandate To Make A Digital Difference
By Jo ShorthouseDiogo Rau, chief information and digital officer at Lilly, talks to In Vivo about the company’s plans for making big and disruptive changes using digital strategy to speed up drug development.

-
Interviews
Panthera On The SMO Model, Responsible Growth Priorities And The Hybridized Trial Of The Future
By Jo ShorthouseIn this episode of the In Vivo podcast, Jo Shorthouse speaks with the co-founder and chief commercial officer of the site management organization, Panthera Biopartners. The discussion centers on the practicalities and reality of running clinical trial sites as a business, and the age-old challenge of patient recruitment.

-
Analysis
Teva’s New CEO Francis: No Revolution, But New Strategy Will Not Be Marginal
By Dean RudgeOn the final day of the annual J.P. Morgan Healthcare Conference, Richard Francis, with vast experience at Biogen and Sandoz under his belt, faced investors for the first time as Teva’s CEO, after replacing Kåre Schultz on 1 January.

-
News
Califf: Decades Of Follow-Up Necessary For Gene Therapy
By Sarah Karlin-SmithFDA Commissioner Califf acknowledges that regulatory pathways for gene therapies are still being developed and that many factors outside of the modality impact agency requirements as he emphasized the need for long-term follow up due to the unknowns of gene modification.

-
Interviews
Rocket Pharmaceuticals’ CEO Talks Gene Platforms and Spiritual Leadership
By David WildThe trajectory of Rocket Pharmaceuticals, a clinical-stage gene therapy company, has been marked by a series of impressive milestones. At least partial credit for those accomplishments goes to CEO Gaurav Shah, who co-founded the company in 2015 and has combined scientific, business and managerial savvy to progress the company through two regulatory filings this year. Shah recently spoke to In Vivo about the company and his own leadership style.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.